PPARG and lipodystrophy: Therefore, to examine whether lipodystrophy in aKO mice resulted from a reduction of PPARγ activity, we next orally administered a synthetic PPARγ agonist (pioglitazone [Pio], 30 mg/kg/day) to the mice for 10 weeks.